PSCA-Targeted CAR-T Cells therapy (Bellicum Pharmaceuticals)

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NamePSCA-Targeted CAR-T Cells therapy (Bellicum Pharmaceuticals)
Drug Alias NameBPX-601
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionProstate stem cell antigen modulatorsT lymphocyte replacements
TargetsProstate stem cell antigen
Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBellicum Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBellicum Pharmaceuticals IncRegeneron Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A